Core Message
Bone mineral density (BMD) of the lumbar area and femoral neck measured by DEXA showed reduced values in untreated patients with Laron syndrome, however calculation of the volumetric density (BMAD) revealed normal values. IGF-I and alendronate treatment improved the low BMD values. Whether low BMD in IGF-I and hGH deficient patients should be treated remains controversial.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Bachrach LK, Marcus R, Ott SM, Rosenbloom AL, Vasconez O, Martinez AL, Rosenfeld RG, Guevara-Aguirre J (1998) Bone mineral, histomorphometry, and body composition in adults with growth hormone receptor deficiency. J Bone Miner Res 13:415–421
Benbassat CA, Wasserman M, Laron Z (1999) Changes in bone mineral density after discontinuation and early re-institution of growth hormone (GH) in patients with childhood-onset GH deficiency. Growth Horm IGF Res 9:290–295
Benbassat CA, Eshed V, Kamjin M, Laron Z (2003) Are adult patients with Laron syndrome osteopenic? A comparison between dual-energy X-ray absorptiometry and volumetric bone densities. J Clin Endocrinol Metab 88:4586–4589
Eshed V, Benbassat CA, Laron Z (2006) Effect of alendronate on bone mineral density in adult patients with Laron syndrome (primary growth hormone insensitivity). Growth Horm IGF Res 16:119–124
Glorieux H, Pettifor JM, Juppner H (eds) (2003) Pediatric bone, biology and diseases. Academic Press, Amsterdam
Holmes SJ, Economou G, Whitehouse RW, Adams JE, Shalet SM (1994) Reduced bone mineral density in patients with adult onset growth hormone deficiency. J Clin Endocrinol Metab 78:669–674
Kann P, Piepkorn B, Schehler B, Andreas J, Lotz J, Prellwitz W, Beyer J (1998) Effect of long-term treatment with GH on bone metabolism, bone mineral density and bone elasticity in GH-deficient adults. Clin Endocrinol (Oxf) 48:561–568
Katzman DK, Bachrach LK, Carter DR, Marcus R (1991) Clinical and anthropometric correlates of bone mineral acquisition in healthy adolescent girls. J Clin Endocrinol Metab 73:1332–1339
Laron Z (1999) Natural history of the classical form of primary growth hormone (GH) resistance (Laron syndrome). J Pediatr Endocrinol Metab 12:231–249
Laron Z, Klinger B (1994) IGF-I treatment of adult patients with Laron syndrome: preliminary results. Clin Endocrinol 41:631–638
Ohlsson C, Bengtsson BA, Isaksson OG, Andreassen TT, Slootweg MC (1998) Growth hormone and bone. Endocr Rev 19:55–79
Sneppen SB, Hoeck HC, Kollerup G, Sørensen OH, Laurberg P, Feldt-Rasmussen U (2002) Bone mineral content and bone metabolism during physiological GH treatment in GH-deficient adults – an 18-month randomised, placebo-controlled, double blinded trial. Eur J Endocrinol 146:187–195
Vandeweghe M, Taelman P, Kaufman JM (1993) Short and long-term effects of growth hormone treatment on bone turnover and bone mineral content in adult growth hormone-deficient males. Clin Endocrinol (Oxf) 39:409–415
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Berlin Heidelberg
About this chapter
Cite this chapter
Laron, Z. (2011). Bone Mineral Density in Untreated and IGF-I or Alendronate-Treated Patients with Laron Syndrome. In: Laron, Z., Kopchick, J. (eds) Laron Syndrome - From Man to Mouse. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-11183-9_18
Download citation
DOI: https://doi.org/10.1007/978-3-642-11183-9_18
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-11182-2
Online ISBN: 978-3-642-11183-9
eBook Packages: MedicineMedicine (R0)